http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 12 May 2026 16:01:51 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Earnings/Lineage+Cell+Therapeutics+%28LCTX%29+Misses+Q1+EPS+by+2c/26477445.html <p>Lineage Cell Therapeutics (NYSE: LCTX) reported Q1 EPS of ($0.03), $0.02 worse than the analyst estimate of ($0.01). Revenue for the quarter came in at $1.73 million versus the consensus estimate of $3.43 million.</p><p>For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) <a href="http://www.streetinsider.com/ec_earnings.php?q=LCTX">click here</a>.</p> http://www.streetinsider.com/Earnings/Lineage+Cell+Therapeutics+%28LCTX%29+Misses+Q1+EPS+by+2c/26477445.html Tue, 12 May 2026 16:01:51 -0400 LCTX http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html <ul class="bwlistdisc"> <li> <b>Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026</b> </li> <li> <b>Launched New Corneal Endothelial Disease Cell Therapy Program</b> </li> <li> <b>Met First Milestone with AlloSCOPE™ 5D Manufacturing Initiative</b> </li> <li> <b>Treated Second Chronic SCI Patient in OPC1 DOSED Device Safety Study</b> </li> <li> <b>Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD, as its Founding Member</b> </li> <li> <b>Appointed Priyantha Herath, MD, PhD, as Senior Vice President &amp; Head of Clinical</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54533062&amp;newsitemid=20260512098382&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=11991d433f656bead5fae35ef81cfc71" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html Tue, 12 May 2026 16:01:00 -0400 A.02973684 A.36512754 A.40151759 A.41958093 LCTX LCTX O.00050368 O.00285735 O.01207978 O.02770996 O.31789473 http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html <ul class="bwlistdisc"> <li> <b>Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026</b> </li> <li> <b>Launched New Corneal Endothelial Disease Cell Therapy Program</b> </li> <li> <b>Met First Milestone with AlloSCOPE™ 5D Manufacturing Initiative</b> </li> <li> <b>Treated Second Chronic SCI Patient in OPC1 DOSED Device Safety Study</b> </li> <li> <b>Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD, as its Founding Member</b> </li> <li> <b>Appointed Priyantha Herath, MD, PhD, as Senior Vice President &amp; Head of Clinical</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54533062&amp;newsitemid=20260512098382&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=11991d433f656bead5fae35ef81cfc71" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html Tue, 12 May 2026 16:01:00 -0400 A.02973684 A.36512754 A.40151759 A.41958093 LCTX LCTX O.00050368 O.00285735 O.01207978 O.02770996 O.31789473 http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html <ul class="bwlistdisc"> <li> <b>Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026</b> </li> <li> <b>Launched New Corneal Endothelial Disease Cell Therapy Program</b> </li> <li> <b>Met First Milestone with AlloSCOPE™ 5D Manufacturing Initiative</b> </li> <li> <b>Treated Second Chronic SCI Patient in OPC1 DOSED Device Safety Study</b> </li> <li> <b>Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD, as its Founding Member</b> </li> <li> <b>Appointed Priyantha Herath, MD, PhD, as Senior Vice President &amp; Head of Clinical</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54533062&amp;newsitemid=20260512098382&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=11991d433f656bead5fae35ef81cfc71" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html Tue, 12 May 2026 16:01:00 -0400 A.02973684 A.36512754 A.40151759 A.41958093 LCTX LCTX O.00050368 O.00285735 O.01207978 O.02770996 O.31789473 http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html <ul class="bwlistdisc"> <li> <b>Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026</b> </li> <li> <b>Launched New Corneal Endothelial Disease Cell Therapy Program</b> </li> <li> <b>Met First Milestone with AlloSCOPE™ 5D Manufacturing Initiative</b> </li> <li> <b>Treated Second Chronic SCI Patient in OPC1 DOSED Device Safety Study</b> </li> <li> <b>Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD, as its Founding Member</b> </li> <li> <b>Appointed Priyantha Herath, MD, PhD, as Senior Vice President &amp; Head of Clinical</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54533062&amp;newsitemid=20260512098382&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=11991d433f656bead5fae35ef81cfc71" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html Tue, 12 May 2026 16:01:00 -0400 A.02973684 A.36512754 A.40151759 A.41958093 LCTX LCTX O.00050368 O.00285735 O.01207978 O.02770996 O.31789473 http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html <ul class="bwlistdisc"> <li> <b>Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026</b> </li> <li> <b>Launched New Corneal Endothelial Disease Cell Therapy Program</b> </li> <li> <b>Met First Milestone with AlloSCOPE™ 5D Manufacturing Initiative</b> </li> <li> <b>Treated Second Chronic SCI Patient in OPC1 DOSED Device Safety Study</b> </li> <li> <b>Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD, as its Founding Member</b> </li> <li> <b>Appointed Priyantha Herath, MD, PhD, as Senior Vice President &amp; Head of Clinical</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54533062&amp;newsitemid=20260512098382&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=11991d433f656bead5fae35ef81cfc71" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html Tue, 12 May 2026 16:01:00 -0400 A.02973684 A.36512754 A.40151759 A.41958093 LCTX LCTX O.00050368 O.00285735 O.01207978 O.02770996 O.31789473 http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html <ul class="bwlistdisc"> <li> <b>Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026</b> </li> <li> <b>Launched New Corneal Endothelial Disease Cell Therapy Program</b> </li> <li> <b>Met First Milestone with AlloSCOPE™ 5D Manufacturing Initiative</b> </li> <li> <b>Treated Second Chronic SCI Patient in OPC1 DOSED Device Safety Study</b> </li> <li> <b>Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD, as its Founding Member</b> </li> <li> <b>Appointed Priyantha Herath, MD, PhD, as Senior Vice President &amp; Head of Clinical</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54533062&amp;newsitemid=20260512098382&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=11991d433f656bead5fae35ef81cfc71" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html Tue, 12 May 2026 16:01:00 -0400 A.02973684 A.36512754 A.40151759 A.41958093 LCTX LCTX O.00050368 O.00285735 O.01207978 O.02770996 O.31789473 http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html <ul class="bwlistdisc"> <li> <b>Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026</b> </li> <li> <b>Launched New Corneal Endothelial Disease Cell Therapy Program</b> </li> <li> <b>Met First Milestone with AlloSCOPE™ 5D Manufacturing Initiative</b> </li> <li> <b>Treated Second Chronic SCI Patient in OPC1 DOSED Device Safety Study</b> </li> <li> <b>Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD, as its Founding Member</b> </li> <li> <b>Appointed Priyantha Herath, MD, PhD, as Senior Vice President &amp; Head of Clinical</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54533062&amp;newsitemid=20260512098382&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=11991d433f656bead5fae35ef81cfc71" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html Tue, 12 May 2026 16:01:00 -0400 A.02973684 A.36512754 A.40151759 A.41958093 LCTX LCTX O.00050368 O.00285735 O.01207978 O.02770996 O.31789473 http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html <ul class="bwlistdisc"> <li> <b>Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026</b> </li> <li> <b>Launched New Corneal Endothelial Disease Cell Therapy Program</b> </li> <li> <b>Met First Milestone with AlloSCOPE™ 5D Manufacturing Initiative</b> </li> <li> <b>Treated Second Chronic SCI Patient in OPC1 DOSED Device Safety Study</b> </li> <li> <b>Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD, as its Founding Member</b> </li> <li> <b>Appointed Priyantha Herath, MD, PhD, as Senior Vice President &amp; Head of Clinical</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54533062&amp;newsitemid=20260512098382&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=11991d433f656bead5fae35ef81cfc71" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html Tue, 12 May 2026 16:01:00 -0400 A.02973684 A.36512754 A.40151759 A.41958093 LCTX LCTX O.00050368 O.00285735 O.01207978 O.02770996 O.31789473 http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html <ul class="bwlistdisc"> <li> <b>Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026</b> </li> <li> <b>Launched New Corneal Endothelial Disease Cell Therapy Program</b> </li> <li> <b>Met First Milestone with AlloSCOPE™ 5D Manufacturing Initiative</b> </li> <li> <b>Treated Second Chronic SCI Patient in OPC1 DOSED Device Safety Study</b> </li> <li> <b>Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD, as its Founding Member</b> </li> <li> <b>Appointed Priyantha Herath, MD, PhD, as Senior Vice President &amp; Head of Clinical</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54533062&amp;newsitemid=20260512098382&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=11991d433f656bead5fae35ef81cfc71" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html Tue, 12 May 2026 16:01:00 -0400 A.02973684 A.36512754 A.40151759 A.41958093 LCTX LCTX O.00050368 O.00285735 O.01207978 O.02770996 O.31789473 http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html <ul class="bwlistdisc"> <li> <b>Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026</b> </li> <li> <b>Launched New Corneal Endothelial Disease Cell Therapy Program</b> </li> <li> <b>Met First Milestone with AlloSCOPE™ 5D Manufacturing Initiative</b> </li> <li> <b>Treated Second Chronic SCI Patient in OPC1 DOSED Device Safety Study</b> </li> <li> <b>Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD, as its Founding Member</b> </li> <li> <b>Appointed Priyantha Herath, MD, PhD, as Senior Vice President &amp; Head of Clinical</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54533062&amp;newsitemid=20260512098382&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=11991d433f656bead5fae35ef81cfc71" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html Tue, 12 May 2026 16:01:00 -0400 A.02973684 A.36512754 A.40151759 A.41958093 LCTX LCTX O.00050368 O.00285735 O.01207978 O.02770996 O.31789473 http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html <ul class="bwlistdisc"> <li> <b>Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026</b> </li> <li> <b>Launched New Corneal Endothelial Disease Cell Therapy Program</b> </li> <li> <b>Met First Milestone with AlloSCOPE™ 5D Manufacturing Initiative</b> </li> <li> <b>Treated Second Chronic SCI Patient in OPC1 DOSED Device Safety Study</b> </li> <li> <b>Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD, as its Founding Member</b> </li> <li> <b>Appointed Priyantha Herath, MD, PhD, as Senior Vice President &amp; Head of Clinical</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54533062&amp;newsitemid=20260512098382&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=11991d433f656bead5fae35ef81cfc71" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html Tue, 12 May 2026 16:01:00 -0400 A.02973684 A.36512754 A.40151759 A.41958093 LCTX LCTX O.00050368 O.00285735 O.01207978 O.02770996 O.31789473 http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html <ul class="bwlistdisc"> <li> <b>Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026</b> </li> <li> <b>Launched New Corneal Endothelial Disease Cell Therapy Program</b> </li> <li> <b>Met First Milestone with AlloSCOPE™ 5D Manufacturing Initiative</b> </li> <li> <b>Treated Second Chronic SCI Patient in OPC1 DOSED Device Safety Study</b> </li> <li> <b>Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD, as its Founding Member</b> </li> <li> <b>Appointed Priyantha Herath, MD, PhD, as Senior Vice President &amp; Head of Clinical</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54533062&amp;newsitemid=20260512098382&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=11991d433f656bead5fae35ef81cfc71" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html Tue, 12 May 2026 16:01:00 -0400 A.02973684 A.36512754 A.40151759 A.41958093 LCTX LCTX O.00050368 O.00285735 O.01207978 O.02770996 O.31789473 http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html <ul class="bwlistdisc"> <li> <b>Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026</b> </li> <li> <b>Launched New Corneal Endothelial Disease Cell Therapy Program</b> </li> <li> <b>Met First Milestone with AlloSCOPE™ 5D Manufacturing Initiative</b> </li> <li> <b>Treated Second Chronic SCI Patient in OPC1 DOSED Device Safety Study</b> </li> <li> <b>Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD, as its Founding Member</b> </li> <li> <b>Appointed Priyantha Herath, MD, PhD, as Senior Vice President &amp; Head of Clinical</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54533062&amp;newsitemid=20260512098382&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=11991d433f656bead5fae35ef81cfc71" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html Tue, 12 May 2026 16:01:00 -0400 A.02973684 A.36512754 A.40151759 A.41958093 LCTX LCTX O.00050368 O.00285735 O.01207978 O.02770996 O.31789473 http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html <ul class="bwlistdisc"> <li> <b>Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026</b> </li> <li> <b>Launched New Corneal Endothelial Disease Cell Therapy Program</b> </li> <li> <b>Met First Milestone with AlloSCOPE™ 5D Manufacturing Initiative</b> </li> <li> <b>Treated Second Chronic SCI Patient in OPC1 DOSED Device Safety Study</b> </li> <li> <b>Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD, as its Founding Member</b> </li> <li> <b>Appointed Priyantha Herath, MD, PhD, as Senior Vice President &amp; Head of Clinical</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54533062&amp;newsitemid=20260512098382&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=11991d433f656bead5fae35ef81cfc71" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html Tue, 12 May 2026 16:01:00 -0400 A.02973684 A.36512754 A.40151759 A.41958093 LCTX LCTX O.00050368 O.00285735 O.01207978 O.02770996 O.31789473 http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html <ul class="bwlistdisc"> <li> <b>Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026</b> </li> <li> <b>Launched New Corneal Endothelial Disease Cell Therapy Program</b> </li> <li> <b>Met First Milestone with AlloSCOPE™ 5D Manufacturing Initiative</b> </li> <li> <b>Treated Second Chronic SCI Patient in OPC1 DOSED Device Safety Study</b> </li> <li> <b>Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD, as its Founding Member</b> </li> <li> <b>Appointed Priyantha Herath, MD, PhD, as Senior Vice President &amp; Head of Clinical</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54533062&amp;newsitemid=20260512098382&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=11991d433f656bead5fae35ef81cfc71" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html Tue, 12 May 2026 16:01:00 -0400 A.02973684 A.36512754 A.40151759 A.41958093 LCTX LCTX O.00050368 O.00285735 O.01207978 O.02770996 O.31789473 http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html <ul class="bwlistdisc"> <li> <b>Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026</b> </li> <li> <b>Launched New Corneal Endothelial Disease Cell Therapy Program</b> </li> <li> <b>Met First Milestone with AlloSCOPE™ 5D Manufacturing Initiative</b> </li> <li> <b>Treated Second Chronic SCI Patient in OPC1 DOSED Device Safety Study</b> </li> <li> <b>Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD, as its Founding Member</b> </li> <li> <b>Appointed Priyantha Herath, MD, PhD, as Senior Vice President &amp; Head of Clinical</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54533062&amp;newsitemid=20260512098382&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=11991d433f656bead5fae35ef81cfc71" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html Tue, 12 May 2026 16:01:00 -0400 A.02973684 A.36512754 A.40151759 A.41958093 LCTX LCTX O.00050368 O.00285735 O.01207978 O.02770996 O.31789473 http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html <ul class="bwlistdisc"> <li> <b>Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026</b> </li> <li> <b>Launched New Corneal Endothelial Disease Cell Therapy Program</b> </li> <li> <b>Met First Milestone with AlloSCOPE™ 5D Manufacturing Initiative</b> </li> <li> <b>Treated Second Chronic SCI Patient in OPC1 DOSED Device Safety Study</b> </li> <li> <b>Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD, as its Founding Member</b> </li> <li> <b>Appointed Priyantha Herath, MD, PhD, as Senior Vice President &amp; Head of Clinical</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54533062&amp;newsitemid=20260512098382&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=11991d433f656bead5fae35ef81cfc71" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html Tue, 12 May 2026 16:01:00 -0400 A.02973684 A.36512754 A.40151759 A.41958093 LCTX LCTX O.00050368 O.00285735 O.01207978 O.02770996 O.31789473 http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html <ul class="bwlistdisc"> <li> <b>Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026</b> </li> <li> <b>Launched New Corneal Endothelial Disease Cell Therapy Program</b> </li> <li> <b>Met First Milestone with AlloSCOPE™ 5D Manufacturing Initiative</b> </li> <li> <b>Treated Second Chronic SCI Patient in OPC1 DOSED Device Safety Study</b> </li> <li> <b>Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD, as its Founding Member</b> </li> <li> <b>Appointed Priyantha Herath, MD, PhD, as Senior Vice President &amp; Head of Clinical</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54533062&amp;newsitemid=20260512098382&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=11991d433f656bead5fae35ef81cfc71" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html Tue, 12 May 2026 16:01:00 -0400 A.02973684 A.36512754 A.40151759 A.41958093 LCTX LCTX O.00050368 O.00285735 O.01207978 O.02770996 O.31789473 http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html <ul class="bwlistdisc"> <li> <b>Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026</b> </li> <li> <b>Launched New Corneal Endothelial Disease Cell Therapy Program</b> </li> <li> <b>Met First Milestone with AlloSCOPE™ 5D Manufacturing Initiative</b> </li> <li> <b>Treated Second Chronic SCI Patient in OPC1 DOSED Device Safety Study</b> </li> <li> <b>Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD, as its Founding Member</b> </li> <li> <b>Appointed Priyantha Herath, MD, PhD, as Senior Vice President &amp; Head of Clinical</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54533062&amp;newsitemid=20260512098382&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=11991d433f656bead5fae35ef81cfc71" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html Tue, 12 May 2026 16:01:00 -0400 A.02973684 A.36512754 A.40151759 A.41958093 LCTX LCTX O.00050368 O.00285735 O.01207978 O.02770996 O.31789473 http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html <ul class="bwlistdisc"> <li> <b>Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026</b> </li> <li> <b>Launched New Corneal Endothelial Disease Cell Therapy Program</b> </li> <li> <b>Met First Milestone with AlloSCOPE™ 5D Manufacturing Initiative</b> </li> <li> <b>Treated Second Chronic SCI Patient in OPC1 DOSED Device Safety Study</b> </li> <li> <b>Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD, as its Founding Member</b> </li> <li> <b>Appointed Priyantha Herath, MD, PhD, as Senior Vice President &amp; Head of Clinical</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54533062&amp;newsitemid=20260512098382&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=11991d433f656bead5fae35ef81cfc71" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html Tue, 12 May 2026 16:01:00 -0400 A.02973684 A.36512754 A.40151759 A.41958093 LCTX LCTX O.00050368 O.00285735 O.01207978 O.02770996 O.31789473 http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html <ul class="bwlistdisc"> <li> <b>Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026</b> </li> <li> <b>Launched New Corneal Endothelial Disease Cell Therapy Program</b> </li> <li> <b>Met First Milestone with AlloSCOPE™ 5D Manufacturing Initiative</b> </li> <li> <b>Treated Second Chronic SCI Patient in OPC1 DOSED Device Safety Study</b> </li> <li> <b>Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD, as its Founding Member</b> </li> <li> <b>Appointed Priyantha Herath, MD, PhD, as Senior Vice President &amp; Head of Clinical</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54533062&amp;newsitemid=20260512098382&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=11991d433f656bead5fae35ef81cfc71" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html Tue, 12 May 2026 16:01:00 -0400 A.02973684 A.36512754 A.40151759 A.41958093 LCTX LCTX O.00050368 O.00285735 O.01207978 O.02770996 O.31789473 http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html <ul class="bwlistdisc"> <li> <b>Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026</b> </li> <li> <b>Launched New Corneal Endothelial Disease Cell Therapy Program</b> </li> <li> <b>Met First Milestone with AlloSCOPE™ 5D Manufacturing Initiative</b> </li> <li> <b>Treated Second Chronic SCI Patient in OPC1 DOSED Device Safety Study</b> </li> <li> <b>Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD, as its Founding Member</b> </li> <li> <b>Appointed Priyantha Herath, MD, PhD, as Senior Vice President &amp; Head of Clinical</b> </li> </ul> <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54533062&amp;newsitemid=20260512098382&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=11991d433f656bead5fae35ef81cfc71" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical http://www.streetinsider.com/Business+Wire/Lineage+Cell+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Provides+Business+Update/26477415.html Tue, 12 May 2026 16:01:00 -0400 A.02973684 A.36512754 A.40151759 A.41958093 LCTX LCTX O.00050368 O.00285735 O.01207978 O.02770996 O.31789473 http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+to+Report+First+Quarter+2026+Financial+Results+and+Provide+Business+Update+on+May+12%2C+2026/26430128.html <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54523807&amp;newsitemid=20260505977292&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=bf69e7e5deb4cf02bb0fb95cb3256905" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical conditions, today announced that it will report its first quarter 2026 financial and operating results on Thursday, May 12, 2026, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, May 12, 2026, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2026 financial and operating results and to provide a business update. </p><p> <b>Conference http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+to+Report+First+Quarter+2026+Financial+Results+and+Provide+Business+Update+on+May+12%2C+2026/26430128.html Tue, 05 May 2026 08:00:00 -0400 A.36512754 A.40151759 LCTX LCTX O.00050368 O.01207978 O.02770996 http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+to+Report+First+Quarter+2026+Financial+Results+and+Provide+Business+Update+on+May+12%2C+2026/26430128.html <p> CARLSBAD, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54523807&amp;newsitemid=20260505977292&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=bf69e7e5deb4cf02bb0fb95cb3256905" shape="rect">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical conditions, today announced that it will report its first quarter 2026 financial and operating results on Thursday, May 12, 2026, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, May 12, 2026, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first quarter 2026 financial and operating results and to provide a business update. </p><p> <b>Conference http://www.streetinsider.com/Press+Releases/Lineage+Cell+Therapeutics+to+Report+First+Quarter+2026+Financial+Results+and+Provide+Business+Update+on+May+12%2C+2026/26430128.html Tue, 05 May 2026 08:00:00 -0400 A.36512754 A.40151759 LCTX LCTX O.00050368 O.01207978 O.02770996